| P50 | author | Robert A. Stern | Q34445890 |
| | Mkaya Mwamburi | Q87110939 |
| P2093 | author name string | Rhoda Au | |
| | Haihao Zhu | |
| | James Rosenzweig | |
| | Wei Qiao Qiu | |
| | Huajie Li | |
| | Elizabeth Liebson | |
| | Max Wallack | |
| P2860 | cites work | Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation | Q22008492 |
| | “Mini-mental state” | Q25938989 |
| | The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics | Q27860914 |
| | Amyloid β (Aβ) peptide directly activates amylin-3 receptor subtype by triggering multiple intracellular signaling pathways | Q30175699 |
| | The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery | Q33454243 |
| | Islet amyloid and type 2 diabetes mellitus | Q33912902 |
| | Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer's disease. | Q34167833 |
| | Amylin deposition in the brain: A second amyloid in Alzheimer disease? | Q34352928 |
| | Human but not rat amylin shares neurotoxic properties with Abeta42 in long-term hippocampal and cortical cultures | Q34779219 |
| | Association between amylin and amyloid-β peptides in plasma in the context of apolipoprotein E4 allele | Q35092684 |
| | Amylin agonists: a novel approach in the treatment of diabetes | Q35961978 |
| | Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease | Q36330297 |
| | Increased risk of cognitive impairment in patients with diabetes is associated with metformin | Q37193677 |
| | Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk | Q37193917 |
| | Toxic oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence? | Q37698330 |
| | Amylin and the regulation of appetite and adiposity: recent advances in receptor signaling, neurobiology and pharmacology | Q38062765 |
| | Enhanced amylin-mediated body weight loss in estradiol-deficient diet-induced obese rats | Q42852579 |
| | Suppression of IAPP fibrillation at anionic lipid membranes via IAPP-derived amyloid inhibitors and insulin | Q43163364 |
| | Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study | Q43935519 |
| | Dissecting the role of single regions of an IAPP mimic and IAPP in inhibition of Aβ40 amyloid formation and cytotoxicity. | Q44269390 |
| | An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in insulinoma cell cultures | Q44564031 |
| | Selectively N-methylated soluble IAPP mimics as potent IAPP receptor agonists and nanomolar inhibitors of cytotoxic self-assembly of both IAPP and Aβ40. | Q47752480 |
| | Differential permeability of the blood-brain barrier to two pancreatic peptides: insulin and amylin | Q47849481 |
| | Comparison of the effects of chronic central administration and chronic peripheral administration of islet amyloid polypeptide on food intake and meal pattern in the rat. | Q48114139 |
| | The National Adult Reading Test as a measure of premorbid intelligence: a comparison with estimates derived from demographic variables | Q48484139 |
| | The Nutrition, Aging, and Memory in Elders (NAME) study: design and methods for a study of micronutrients and cognitive function in a homebound elderly population. | Q48562887 |
| | Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition. | Q48869814 |
| | Molecular characterization of the hetero-assembly of β-amyloid peptide with islet amyloid polypeptide. | Q50955641 |
| | Effect of oral antidiabetic agents on plasma amylin level in patients with non-insulin-dependent diabetes mellitus (type 2). | Q51563276 |
| | Direct plasma radioimmunoassay for rat amylin-(1-37): concentrations with acquired and genetic obesity. | Q51594608 |
| | Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. | Q52171785 |
| | Activity of Pramlintide, Rat and Human Amylin but not Aβ1–42at Human Amylin Receptors | Q60516030 |
| | Amylin: localization, effects on cerebral arteries and on local cerebral blood flow in the cat. | Q64965686 |
| | Effects of aging on plasma islet amyloid polypeptide basal level and response to oral glucose load | Q68095355 |
| | Amylin-induced relaxation of the perfused mesenteric arterial bed: meditation by calcitonin gene-related peptide receptors | Q71013459 |
| | Apolipoprotein E ϵ4 and cerebral hemorrhage associated with amyloid angiopathy | Q72007219 |
| | Deficiency of total and nonglycosylated amylin in plasma characterizes subjects with impaired glucose tolerance and type 2 diabetes | Q74184777 |
| | IAPP mimic blocks Abeta cytotoxic self-assembly: cross-suppression of amyloid toxicity of Abeta and IAPP suggests a molecular link between Alzheimer's disease and type II diabetes | Q79489683 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 555-563 | |
| P577 | publication date | 2014-01-01 | |
| P1433 | published in | Journal of Alzheimer's Disease | Q6294755 |
| P1476 | title | Positive association between plasma amylin and cognition in a homebound elderly population | |
| P478 | volume | 42 | |